PTO/SB/08 (2-92) Sheet 1 of 6

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 432722002623	Application Number 09/695,807			
Applicant				
Gregory	y R. MUNDY et al.			
Filing Date October 23, 2000 Group Art Unit-1646 /65 /				
Mailing Date July 10, 2001				

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		09/096,631	43272:20021			June 12, 1998
	2.	8/1988	4,761,471	Urist	530	350	
	3.	1/1994	5,280,040	Labroo et al.	514	457	
	4.	12/1996	5,580,854	Orlowski et al.	514	18	
	5.	3/1998	5,728,844	Muller et al.	548	472	
	6.	6/1998	5,767,152	Nielsen et al.	514	526	
	7.	7/1998	5,780,454	Adams et al.	514	64	
-,	8.	10/1998	5,824,643	Pierce et al.	514	12	
	9.	6/1999	5,910,497	Durette et al.	514	253	
Ro	10.	7/2000	6,083,690	Harris et al.	435	6	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	11.	10/1990	WO 90 11366	WIPO			
	12.	3/1992	WO 92 03125	WIPO			
	13.	10/1993	WO 93 20859	WIPO			
	14.	9/1995	WO 95 24211	WIPO			
	15.	9/1995	WO 95 25533	WIPO			·
	16.	12/1996	WO 96 38590	WIPO			
	17.	3/1997	WO 97 09315	WIPO			
	18.	5/1997	WO 97 15308	WIPO			
	19.	7/1997	WO 97 23457	WIPO			
	20.	10/1997	WO 97 38699	WIPO			
	21.	12/1997	WO 97 48694	WPO			
·	22.	4/1998	WO 98 17267	WÎPQ			
	23.	6/1998	WO 98 25460	WIPO			

EXAMINER: RGITONIEN DATE CONSIDERED: 12/16/02

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92) Sheet 2 of 6

Form PTO-1449			Docket Number 432722002623 Application Nu		umber 09/695,807				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Applicant Gregory R. MUNDY et al.						
			Filing Date October 23, 2000 Group Art Unit 1646						
			Mailing Date July 10, 20	01	<u></u>				
•	24.	1/2000	WO 0002548	WII	20				
	25.	10/1998	DE 197 16 713	Ger	many				
	26.	7/1999	EP 0 931 544	Eur	ope	ļ	ļ		
	27.	4×1993	JP 05 097697	Japa	an	<u> </u>			
			ОТНЕ	R D	OCUMENTS	(includi	ng author, title, Da	ite, Pertinent I	Pages, Etc.)
Examiner Initials	Ref. No.	Title	\		·				
minais	28.	Abu-Amer e 3(11):1189-	et ah, "NF-kB and Bo	ne:	The Breaking Point,	"NATURE	MEDICINE	(1997)	,
	29.	Adams, J. et al., "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents," CANCER RES (1999) 59:2615-2622							
	30.	Adams et al., "Chapter 28. Novel Inhibitors of the Proteasome and their Therapeutic Use in Inflammation," ANNUAL REPORTS IN MEDICINAL CHEMISTRY (1996) 279-288							
	31.	Ahmed et al., "Alopecia Universalis Associated with a Mutation in the Human Hairless Gene," SCIENCE (1998) 279:720-724							
	32.	Bangham et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J MOL BIOL (1965) 23:238-252							
	33.	Barnes et al., "Nuclear Factor -kB - A Pivotal Transcription Factor in Chronic Inflammatory Diseases," NEW ENGL J MED (1997) 336:1066-1071							
	34.	Baumeister et al., "The Proteasome: Paradigm of a Self-Compartmentalizing Protease," CELL(1998) 92:367-380							
	35.	Beck et al., "Rapid Publication TGF-β ₁ Induces Bone Closure of Skull Defects," J BONE MINER RES (1991) 6(11):1257-1265							
	36.	Bellows et al., "Determination of the Capacity for Rroliferation and Differentiation of Osteoprogenitor Cells in the Presence and Absence and Absence of Dexamethasone," DEVELOP BIOL (1990) 140:132-138							
	37.	Blessing et al., "Transgenic Mice as a Model to Study the Role of TGF-β-Related Molecules in Hair Follicles," GENES AND DEVELOP (1992) 7:204-215							
	38.	Burgener et al., "Fluoride Increase Tyrosine Kinase Activity in Osteoblast-like Cells: Regulatory Role for the Stimulation of Cell Proliferation and Pi Transport Across the Plasma Membrane," J BONE MINER RES (1995) 10:164-171							
	39.	Caplan, "Mesenchymal Stem Cells" J ORTHOP RES (1991) 9:641-650							
	40.	Casez et al.	"Dual-Energy X-Ra	y Ab	sorptiometry for Me	easuring Tol	al Bone Mine	ral Conten	it in the
EXAMI			onen		DATE CONS	garine <u>-</u>	12/16		
EXAMII conform	NER: Init	ial if citation con not considered. I	sidered, whether or not th nclude a copy of this form	e citat with	next communication to a	фрисана			
PTO/SB/ 08				*	Patent and Trade	mark Office; l	J.S. DEPARTM	ENT OF CO	MMERCE

PTO/SB/08 (2-92) Sheet 3 of 6

Form PTO-1449			Docket Number 432722002623	Application Number 09/695,807		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Gregory R. MUNDY et al.			
(Use several sheets if necessary)			Filing Date October 23, 2000	Group Art Unit 1646		
		·	Mailing Date July 10, 2001			
		Rat:Study of Accuracy and Precision,"				
	41.	Combaret, L. et al., "Manipulation of the Ubiquitin-Proteasome Pathway in Cachexia: Pentoxifylline Suppresses the Activation of 20S and 26S Proteasoms in Muscles from Tumor-Bearing Rats," MOL BIOL REP (1999) 26:95-101				
	42.	Coux, O. et al., "Structure and Functio (1996) 65:801-847				
	43.	Craiu, A. et al., "Lactacystin and Class Subunits and Inhibit Intracellular Prote Antigen Presentation," J BIOL CHEM	ein Degradation and major Histo	y Multiple Proteasome β- compatibility Complex Class I		
	44.	Cui et al., "Lovastatin Prevents Steroid Annual Meeting (September 1996) J B	ONE MINER RES (1996) 11(S	1):S510		
	45.	Ducy et al. "Increased Bone Formation 452				
	46.	Edelman et al., "Controlled and Modu BIOMATERIALS (1991) 12:619-626	lated Release of Basic Fibroblas	ted Release of Basic Fibroblast Growth Factor,"		
	47.	Elofsson et al., Chemistry & Biology (1999) 6.811-822				
***	48.	Ferretti, "Perspectives of pQct Technology Associated To Biomechanical Studies in Skeletal Research Employing Rat Models," BONE (1995) 17:353S-364S				
	49.	Figueiredo-Pereira et al., "A New Inhibitor of the Chymotrypsin-Like Activity of the Multicatalytic Proteinase Complex (20S Proteasome) Induces Accumulation of Ubiquitin-Protein Conjugates in a Neuronal Cell," J NEUROCHEM (1994) 63:1578-1581				
	50.	Franzoso et al., "Requirement for NF-DEV (1997) 11:3482-3496	kB in Osteoclast and B-Cell Dev	velopment," GENES AND		
	51.	Garrett et al, "Specific Inhibitors of the Anabolic Agents in Vivo" Journal of I	e Chymotryptic Component of the Bone and Mineral Research (200	ne Proteasome are Potent Bone 0) 15(Suppl.1):S197		
	52.	Gat et al., "De Novo Hair Follicle Mon β-Catenin in Skin," CELL (1998) 95:6	rphogenesis and Hair Tumors in			
	53.	Ghosh-Choudhery et al., "Immortalize Expressing Transgenic Mice," ENDO	ed Murine Osteoblasts Derived f	rom BMP 2-T-Antigen 39		
	54.	Gowan et al., "Actions of Recombina Resorption in Vitro," J IMMUNOL (1	nt Interleukin 1, Interleukin 2, a 986) 136:2478-2482	nd Interferon-γ on Bone		
176	55.	Groll et al., J. Am. Chem. Soc. (2000)				
	.56.	Guijarro et al. "Lovastatin Inhibits Lipopolysaccharide-induced NF-kB Activation in Human Mesangial Cells," NEPHROL DIAL TRANSPLANT (1996) 11:990-996				
	57.	Gupta et al., "Oral Cyclosporine for the Treatment of Alopecia Areata," J AMER ACAD OF DERMATOLOGY (1990) 22(2):242-250				
EXAMI		12 Gitomen	DATE CONSIDERED: /2/16/02			
EXAMIN conforma	IER: Initi	ial if citation considered, whether or not the citati not considered. Include a copy of this form with r				
PTO/SB/ 08	(2-92)		Patent and Trademark Office; U	S. DEPARTMENT OF COMMERCE		

PTO/SB/ 08 (2-92)

Form PTC)-1449		Docket Number 432722002623	Application Number 09/695,807		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Gregory R. MUNDY et al.			
(Use several sheets if necessary)			Filing Date October 23, 2000	Group Art Unit 1646		
			Mailing Date July 10, 2001			
						
	58.	Hardy et al., "The Secret Life of the H				
	59.	Harris et al. "Effects of Transforming Bone Morphogenetic Protein 2, Osteo mRNA in Long-Term Cultures of Feta 9:855-863	calcin, Osteopontin, Alkaline Ph	iosphatase, and Type I Collagen		
	60.	Hilt, W. et al., "Proteasomes: Destruct	tion as a Programme," TRANS I	BIOCHEM SCI 91996) 21:96-		
	61.	Iotsova et al., "Osteopetrosis in Mice 1289	Lacking NF-kB1 and NF-kB2,"	NATURE MED (1997) 3:1285-		
	62.	Jensen, T.J. et al., "Multiple Proteolyt Processing," CELL (1995) 83:129-13	ic Systems, Including the Protea 5	some, Contribute to CFTR		
RG	63.	Kamiya et al., J. Derm. Sci. (1998) 17	:54-60			
	64.	Kim et al., "Preparation of Multivesic 348	ular Liposomes," BIOCHIM BIO	OPHYS ACTA (1983) 728:339-		
	65.	Kimmel et al., The Effect of Recomb Hormone on the Sleeton of Adult Ost 132:1577-1584	vinant Human (1-84) or Synthetic eopenic Ovariectomized Rats," l	c Human (1-34) Parathyroid ENDOCRINOLOGY (1993)		
	66.	Ksander et al., "Exogenous Transform Formation and Wound Strength in Gus SURG (1990) 211(3):288-294	nces Connective Tissue g by Secondary Intent," ANN			
	67.	neus: Comparison with suited Tomography," CALCIF				
RG	68.	TISSUE INTL (1995) 56:14-18 Law et al., Mol. Cell Biol. (1992) 12:103-111				
	69.	Leserman et al., "Targeting to Cells of Fluorescent Liposomes Covalently Coupled With Monoclonal Antibody or Protein A," NATURE (1980) 288:602-604				
	70.	Liptay et al., "Inhibition of Nuclear Fa Sulfasalazine," BR J PHARMACOL	actor Kappa B and Induction of A (1999) 128(7):1361-1369	Apoptosis in T-Lymphocytes by		
	71.	Lutz, "Effects of Cyclosporin A on Hair," SKIN PHARMACOLOGY (1994) 7:101-104				
	72.	Majeska et al., "Maintenance of Paratl EXP CELL RES (1978) 111:465-467	rathyroid Hormone Response in Clonal Rat Osteosarcoma Lines,"			
	73.	Maupin-Furlow, J.A. et al., "A Proteasome from the methanogenic Archaeon Methanosarcina thermophila," J BIOL CHEM (1995) 270:28617-28622				
	74.	BIOPHYS ACTA (1986) 858:161-168	able Sizes Produced by a Rapid Extrusion Procedure," BIOCHIM 161-168			
	75.	Meng et al., "Epoxomicin, a Potent an		r, Exhibits In Vivo		
EXAMI		RGITONIAN		2/16/02		
EXAMI) conforma	NER: Init	tial if citation considered, whether or not the citati not considered. Include a copy of this form with r	on conforms with MPEP 609. Draw a least communication to applicant.	line through the citation if not in		

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92) Sheet 5 of 6

Form PTO-1449		Docket Number 432722002623	Application Number 09/695,807				
	ION DISCLOSURE CITATION I AN APPLICATION	Applicant Gregory R. MUNDY et al.					
(t	Use several sheets if necessary)	Filing Date October 23, 2000	Group Art Unit 1646				
		Mailing Date July 10, 2001					
	Antiinflammatory Activity" Proceedin (1999) 96(18):10403-10408	gs of the National Academy of S	Sciences of the United States				
RG 76.	Mundy et al., Science (1999) 286:1946	5-1949					
77.	Murray et al., "The Ubiquitin-Proteason Qsteoblastic Cells," EXPERIMENTAL	ome System and Cellular Prolife L CELL RESEARCH (1998) 24	ration and Regulation in 2:460-469				
78.	Olson et al., "Preparation of Liposome Polycarbonate Membranes," BIOCHI	s of Defined Size Deistribution M BIOPHYS ACTA (1979) 557	by Extrusion Through 7:9-23				
79.	Orford et al., "Serine Phosphorylation- BIOL CHEM (1997) 272:24735-24738	Regulated Ubiquitination and E	Degradation of β-Catenin," J				
80.	Ozaki et al., "NF-kB Inhibitors Stimul Resorption by these Cells," FEBS LET		Osteoclasts and Inhibit Bone				
81.	Pahl et al., "The Immunosupressive Fu Factor NF-kB," J EXP MED (1996) 18		ifically Inhibits Transcription				
82.	Patent Abstracts of Japan (August 12,	1993) 17:436 (C-1096)					
83.	Patent Abstracts of Japan (June 20, 193	87) 11:193 (C-430)					
84.	Patent Abstracts of Japan (April 25, 19	86) 10:112 (C-342)					
85.	Peters, J. "Proteasomes: Protein Degra (1994) 19: 377-382	Peters, J. "Proteasomes: Protein Degradation Machines of the Cell," TRENDS BIOCHEM SCI (1994) 19: 377-382					
86.	Rickard et al., "Induction of Rapid Osteoblast Differentiation in Rat Bone Marrow Stromal Cell Cultures by Dexamethasone and BMP-2," DEVELOP BIOL (1994) 161:218-228						
87.	Sampath et al., "Isolation of Osteogeni by Heparin Affinity Chromatography,"	Sampath et al., "Isolation of Osteogenin, an Extracellular Matrix-Associated, Bone-Inductive Protein, by Heparin Affinity Chromatography," PROC NATL ACAD SCI USA (1987) 84:7109-7113					
88.	Sin, N. et al., "Total Synthesis of the Potent Proteasome Inhibitor Epoxomicin: A Useful Tool for Understanding Proteasome Biology," BIORG MED CHEM LETT (1999) 9:2283-2288						
89.	Szoka et al., "Procedure for Preparatio Capture by Reverse-Phase Evaporation	n of Liposomes With Large Inte	mal Aqueous Space and High SA (1978) 75:4194-4198				
90.							
91.	Vinitsky et al., "Inhibition of the Proteolytic Activity of the Multicatalytic Proteinase Complex (Proteasome) by Substrate-Related Peptidyl Aldehydes," J BIOL CHEM. (1994) 269(47):29860-29866						
92.	Wahl et al., "Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B," J CLIN INVEST (1998) 101(5):1163-1174						
93.	Wang et al., "Lipid Clearing Agents in Steroid-Induced Osteoporosis," J FORMOS MED ASSOC (1995) 94:589-592						
EXAMINER:	RGITOMER	DATE CONSIDERED:	12/16/or				
EXAMINER: Init	tial if citation considered, whether or not the citation to considered. Include a copy of this form with n	on conforms with MPEP 609. Draw a least communication to applicant.	ine through the citation if not in				
PTO/SB/ 08 (2-92)		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE					

PTO/SB/08 (2-92) Sheet 6 of 6

Application Number 09/695,807 Docket Number 432722002623 Form PTO-1449 **Applicant** INFORMATION DISCLOSURE CITATION Gregory R. MUNDY et al. IN AN APPLICATION Group Art Unit 1646 Filing Date October 23, 2000 (Use several sheets if necessary) Mailing Date July 10, 2001 Wojcik et al., "Ubiquitin-Mediated Proteolysis Centers in HeLa Cells: Indication from Studies of an 94. Inhibitor of the Chymotrypsin-Like Activity of the Proteasome," EUR J CELL BIOL (1996) 71:311-Wozney, "The Bone Morphogenetic Protein-Eamily as Osteogenesis," MOLEC REPROD DEV 95. (1992) 32:160-167

EXAMINER:

RGIDOMEN

DATE CONSIDERED:

12/16/02

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.